Crouzon's syndrome is a hereditary autosomal-dominant disorder. In its classicform, patients expe rience a premature closure of the cranial sutures, which leads to brachycephaly, p roptosis, a small maxilla, and anomalies of the external and middle ear. In this report, we describ e the case of a father and son who both had a non severe form ofthis disorder. The two men did not have brachycephaly or proptosis, but they did have pto sis and a mixed-type hearing loss.
. Anterior-view photograph (A) ofthe son shows a wide foreh ead and ptosis, while the lateral view (B) shows that the skull shape is mesocephalic and the auricle is slightly large. stenosis of the external ear canal. The external canal appeared to be compressed from the anterior to the posterior.
A bilateral Rinne 's test was negative, and a Weber's test did not lateralize. A pure-tone audiologic test revealed an average bilateral mixed -type 45-dB hearing loss. His sagittal suture was palpable , but the coronal suture was not. The man was otherwise healthy and had a normal intellect. His mother and father were not blood relatives.
We asked the patient's father to come in for an examination. The father suffered from extreme ptosis arid a mixed-type hearing loss. His auricle was macrotic, and his external ear canal was extreme ly stenotic, which nearly blocked the view of the eardrum . He also had a short nose with anteverted nares, a palpab le sagittal suture, and a dolichocephalic skull shape (figure 2).
Discussion
According to Wullstein and Wullstein, the growth of the skull takes place in three phases. ' The frequency and magni tude of laboratory abnormalities were similar in fexolenad inehydrochlorideand placebo-treated patients. Pediatric. Table 2 lists adverse experiences in patients age d 6 tõ r~1t :~r~f t af~~~~~~ĩ~r: Jf o~~r r ĩ~~~~fr~~a~l"bfge~Ĩ wice daily in placebo-controlledseasonal allergic rhinitis studiesin theUnited Slates and Canada thaiweremorecommon with fexofenadine hydrochloride than placebo. 
Back Pain Sinusitis Dizziness
Growsi ness OVERDOSAGE Reportsof fexofenadine hydrochlorideoverdose havebeen infrequent andcontain limited inlormation. However, dlzzlness, drowsiness, and dry mouth have been reported . Singledoses of lexofenadinehydrochlorideup 10 800mg(sixnormal voluntee rsat thisdoselevel), and doses up10 690mgtwicedaily for 1 monlh (three normal volunteers at this dose level ) or 240mg once daily for 1 year (234 normal volunteers at this dose level ) were administered without thedevelopmenl 01 clinically significant adverse events ascompared to placebo. In the event of overdose, cons ider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended . Hemodialysis did not effectively remove fexofenadine hydrochloride from blood (1.7% removed) followi ng terfenadine admi nistration. No deaths occu rred at orai doses of fexolenadine hydrochloride up to 5000 mg/kg in mice (110times the maximum recomme nded dailyoral dose in adults and 200 times themaximumrecom mended daily oral dose in children based onmg/m 2) and upto 5000 mg/kg in rats(230times themaximum recommended daily oral dose in adults and 400limesthemaximum recommended daily oral dose in children basedonmg/m 2) . Additionally, no clinicalsigns of toxicity or grosspathological findingswere observed. In dogs. noevidence of toxicity was observed at oral doses upto 2000mg/kg (300 times the maximum recommended daily oral dose in adults and 530limesthemaximum recommended dai ly oraldose in children base d on mg/m 2) . Prescribing Information asof February 2000 Aventis Pharmaceuticals Inc.
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aS~o usse l , Inc.) US Patents 4,254,129; 5,375,693; 5,578,610 allb0200a
Chr onic Idiopalhic Urticaria Adverse events reported bypatients 12 years of age and olderin placebo-controlled chron ic idiopathic urticaria studies were similar 10those reported in piacebo-controlled seasonal allergic rhinitis studies. In placebocontrolled chronic idiopathic urticaria clinical trials. which incl uded 726 patients 12 years of age and older r~cf~i : b~~n~t ;~f :~~~~~c~r~r [~; h~~d~ĩ~~~~t r~~r e" J~~t~n~~. t ¥at~O 3~?s~~Jv~~~~' e~~~~r :c~~ersp~; ĩt ; ĩcĩJ 12 years and aider whichwere reported bygreater than 2%01 patients treated withfexofenadine hydrochloride 60 mg tablets twice dailyin controlled clinica l studies in the United States and Canada and Ihat were more common with fexofenad ine hydrochloridethan placebo. The safety of fexofenadinehydrochloride in thetreatmenl of chronic idiopathic urticaria in pediatricpatients 6 10 11 years 01 age is based on thesafety profile of fexolenadine hydroch loride in adults and adolescent pat ients atdoses equa l to or higher than therecommended dose (see Pedialric Use).
function, care should betaken in dose selection, and may beuseful to monitor renal function. (See CLINICAL PHARMACOLOGY). ADVERSE REACTIO NS Seasonal Allerg ic Rhinitis Adu lls. In placebo-controlled seasonai allergic rhinitis clinical l rials in pal ients 12years of age andolder, which incl uded 2461 patients rece iving fexofenadinehydrochloride capsu lesat doses of 20mgto 240mgtwicedaily, adve rse eventswere similar in fexofenadine hydrochloride and placebo-treated patients. All adverse events that were reported by greater than 1% of patients who received the recomme nded daily dose of fexofenad ine hydrochloride (60mg capsulestwice daily), and thatwere more common with fexolenad inehydrochloridethan placebo, arelisted in Tab le 1. In a placebo-controlled clinical studyin the UnitedSlates, which included 570pat ients aged 12 years and older receiving fexofenadine hydrochloride tablets at doses of 120 or 180 mgonce daily, adverse events were similar in fexolenadi nehydrochloride and placebo-treated patients. Table 1 also lists adverse experiences thaiwere reported bygreater than 2% of patients treated withfexofenadine hydrochloride tablets at doses of 180 mgonce dai ly and thai were more commo n wilh fexofenadine hydrochloridethan placebo. 
The changes in plasma levels were within therangeof plasma levels achieved Inadequate and well-con trolled clinical trials. Themechanism 01 these interactions hasbeen evaluated in in vitro, in situ, and in vivo ani mal modeis. These studies indi cate Ihat ketoco nazole or erythromyci n co-adm inistration enhances texotenadine gastrointestinal absorption . In vivoanimal studies alsosuggest that in addi tion 10 increasing absorption, ketoconazole decreases fexofenadine hydrochloride gast rointesl inal secrelion, while erythromycin may alsodecrease biliaryexcretion. Drug InleractlonswithAnlaclds Adminlstratlon of 120 mgof fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an alumi num and magnesium contalninq antacid (Maalox0) decreased fexofenad ineAUC by 41% andC max by43%. ALLEG RA should not betaken closely in timewith aluminum and magnesium containingantacids.
Carcinogenesis Mutagenesi s Impa irment01 Fertility
The carcinogenic potential and reproductivetoxicity of fexolenadinehydrochloridewere assessed using terfenadine studieswi th adequate fexolenadine hydrochl oride exposure(based onplasma area-under-the-concentrationvs. lime [AUC)val ues). Noevidence of carcinogenicity was observed in an1a-monthstudy in mice and in a24-month studyIn rats at oral doses up to 150mg/kg 01 terfenadine(whichledto fexolenadineexposuresthat In rat fertility studles, dose-r e l a t e~reductions in implants and increases in post implantation losses were observed at anoral dose of 150 mglkg of terfenadine(whichled to fexofenadine hydrochloride exposuresthat : J;o~~fo' r~~~~~t:~U l r S) l i mes the exposure of the maximum recommended daily oral dose of fexole nadinẽ Teralogenlc Effecls: Calegory C. There was no evidence of teratogenicity in rats or rabbits at oral doses 01 terfenadine up to 300 mg/kg (which led to fexofenadine exposures thatwere approximately 4 and 31 times, respectivel y,theexposure from the maxi mum recommended daily oral dose of fexofenadine in adults).~:~~a~~Y " oO n l ad ĩ~~: t~o~~~l i~e~e~~mr j~~~i :~Ut~~~~~e~i i~~~~~\~~~ef~' t t : xo f e nad i n e should be used during NonteralOgenreEffects. Dose-related decreases in pupweig ht gai n and survival were observed in rats exposed 10anoral dose 01150 mglkg of terfenadine (approximately 3 times Ihemaximum recommended dailyoral dose 01fexofenadinehydrochloride in adul ts based oncomparison of fexofenad inehydrochlorideAUCs). Nursing Mothers Thereareno adeq uate and well-cont rolled studies in women duringlactation. Because many drugs areexcreted in human milk, caulion should be exercised when texofenadine hydrochloride is administered to a nursing woman.
ĩ~~~~O~~t~~~~oĩe~~Jtt i :~s p6e~~a~r 1/: ; ĩ~: "~dĩ~al td s~~e~oi r~Ĩi l j ; fx~f e~~~Y~"~~; o~~r~da;b othadultand pediatric patients at doses equal to or higher than therecommended doses. The safetyof ALLEGRA tablets at a dose of 30 mgtwice daily has been demonstratedin 438pediatric patients 6 to 11years of age intwoplacebo-controlled 2-week seasonal allergic rhini lis trials. Thesafety at ALLEGRA for Ihetreatmenl of chronic idiopalhic urticaria in patients 6 to 11years of age is based oncross-study comparison of thepharm acokineti cs of ALLEGRA in adult and pediatric patients and on thesatety profile of fexofe nadinein both adultand pedialric patients at doses equal to or higherthan therecommended dose. Theeffectiveness of ALLEGRA for the treatment of seasonal allergic rhinitis in pat ients 6 to 11 years of age was dem onstrated in one trial (n=411) in which ALLEGRA tablets 30 mg twice daily significantly reduced total symptom scores compared to placebo, along with extrapolation of demonstrated efficacy in patients ages 12yearsandabove,and thepharmacokinetic comparisonsIn adults andchildren. Theeffectiveness of ALLEGRA for the lreatment of chronic idiopathic urticaria in patient s 6 to 11years 01age is based onanextrapolation of thedemonstrated efficacy of ALLEGRA in adultswithIhis condition and the likeli hoodthatthedisease course, ¥~~h~~f~i~Õd gi J e nc~i~~~e d;~~' ; :C~~W:~u~~~1~:~f Ĩ~i ĩ~\~~g~~Ĩr~a;~a~go:~~~~t~; : ĩ~~~established.
Cli nical studies of ALLEGRA tablets and capsulesdid nol incl udesufficienl numbers of subjects aged 65years and over to determi ne whet her Ihis population responds differently from younger patients. Other reported clinical experience has not idenlified differences in responses between theger iatricand younger patients, This drug is known to be substantially excreted by the kidney, and the risk of toxicreactions to this drug may be greater in patients wilh impaired renalfunction. Because elderly pat ients aremorelikelyto havedecreased renal temporomandibular joint is responsible for the second phase of growth, which occurs between the ages of 2 and 7 years. In the third phase, from age 7 to adulthood, growth takes place primarily in the central part of the face.
The prem ature ossification of a synchondrodial joint at the skull base will change the shape of the skull and will inhibit growth in the central part of the face and the temporal bone.
Patients with Crouzon' s syndro me usually have a normal intell ect. In its most severe form, the syndrome is characterized by turriceph aly, an increase in intracranial pressure, and mental retardation. Crouzon' s syndrome is associated with chronic otitis media and anomalies of the middle ear, including the abse nce of the tympanic membrane , ankylosis of the malleus, deform ity of the stapes with narrowing of the middle ear space, and underdevelopment of the perio steal portions of the labyrinth. Corrective surgery is extensive.
